Skip to main content

Advertisement

SpringerLink
Log in

Comparison of standard-dose and low-dose gemcitabine regimens in pancreatic adenocarcinoma patients: a prospective randomized trial

  • Published:
Journal of Gastroenterology Aims and scope Submit manuscript

Abstract

Background

A prospective, randomized study was performed to determine whether gemcitabine infusion at a low dose (250 mg/m2) is comparable or superior to the standard-dose infusion (1000 mg/m2) in terms of the survival period, clinical benefit, and frequency of adverse effects in patients with advanced pancreatic adenocarcinoma.

Methods

Twenty-five patients who were histologically proven to have locally advanced pancreatic cancer or pancreatic cancer with distant metastases were initially enrolled in the present study. They were treated with gemcitabine infusion at either a dose of 1000 mg/m2 over 30 min (the standard regimen) on days 1, 8, and 15 of every 4-week cycle or at a dose of 250 mg/m2 over 30 min every week. Survival time, response rate, time to treatment failure, clinical benefit response, and adverse effects were compared between the two groups.

Results

Twenty-one patients received gemcitabine for more than 1 month. The median survival period was 7.2 months for patients who received the low-dose infusion regimen, in contrast to 5.2 months for patients administered the standard-dose infusion regimen. The time to treatment failure was 5.6 months for patients in the low-dose infusion regimen, in contrast to 3.4 months for patients in the standard-dose infusion regimen. There were no significant differences in either survival time to time to treatment failure or clinical benefits between the two groups, but the incidence of adverse reactions in patients administered the low-dose therapy was significantly lower than that in patients receiving the standard-dose therapy (P < 0.05). In particular, patients in the standard infusion regimen group experienced more hematologic toxicity than those in the low-dose regimen.

Conclusions

These findings suggest that the low-dose gemcitabine infusion regimen can be continuously administered to patients with locally advanced and systemically spreading pancreatic cancer because of its reduced toxicity, resulting in better quality of life and an improved safety profile as compared to the standard infusion treatment regimen.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. S Egawa K Takeda N Fukuyama F Motoi M Sunamura M Matuno (2003) ArticleTitlePancreatic carcinoma in Japan The national pancreatic cancer registry 46 683–96

    Google Scholar 

  2. Ministry of Health, Labour and Welfare Statistics and Information. 2001 vital statistics of Japan. http://wwwdbtk.mhlw.go.jp/toukei/youran/data13/1-35.htm (in Japanese)

  3. HA Burris SuffixIII MJ Moore J Andersen MR Green ML Rothen MR Modiano et al. (1997) ArticleTitleImprovement in survival and clinical benefit with gemcitabine as first-line therapy for patients with advance pancreas cancer J Clin Oncol 15 2403–13 Occurrence Handle1:CAS:528:DyaK2sXlsFKksLY%3D Occurrence Handle9196156

    CAS  PubMed  Google Scholar 

  4. CF Pollera A Ceribelli M Crecco C Oliva F Calabresi (1997) ArticleTitleProlonged infusion gemcitabine: a clinical phase I study at low- (300 mg/m2) and high-dose (875 mg/m2) levels Invest New Drugs 15 115–21 Occurrence Handle10.1023/A:1005817024382 Occurrence Handle1:CAS:528:DyaK2sXkslynt7g%3D Occurrence Handle9220290

    Article  CAS  PubMed  Google Scholar 

  5. M Tempero W Plunkett V Ruiz Van Haperen J Hainsworth H Hochster R Lenzi et al. (2003) ArticleTitleRandomized phase II comparison of dose-intense gemcitabine: thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma J Clin Oncol 21 3402–8 Occurrence Handle10.1200/JCO.2003.09.140 Occurrence Handle1:CAS:528:DC%2BD2cXpsVKjtLs%3D Occurrence Handle12885837

    Article  CAS  PubMed  Google Scholar 

  6. MM Oken RH Creech DC Tormey J Horton TE Davis ET Mcfadden et al. (1982) ArticleTitleToxicity and response criteria of the Eastern Cooperative Oncology Group Am J Clin Oncol 5 649–55 Occurrence Handle1:STN:280:BiyC2cbntlU%3D Occurrence Handle7165009

    CAS  PubMed  Google Scholar 

  7. R Grunewald JL Abbruzzese P Tarassoff W Plunkett (1991) ArticleTitleSaturation of 2′,2′-difluorodeoxycytidine 5′-triphosphate accumulation by mononuclear cells during a phase I trial of gemcitabine Cancer Chemother Pharmacol 27 258–62 Occurrence Handle10.1007/BF00685109 Occurrence Handle1:STN:280:By6C2M3otFA%3D Occurrence Handle1998982

    Article  CAS  PubMed  Google Scholar 

  8. JL Abbruzzese R Grunewald EA Weeks O Gravel T Adams B Nowak et al. (1991) ArticleTitleA phase I clinical, plasma, and cellular pharmacology study of gemcitabine J Clin Oncol 9 491–8 Occurrence Handle1:STN:280:By6C2MvosFA%3D Occurrence Handle1999720

    CAS  PubMed  Google Scholar 

  9. M Kudo (2003) Contrast harmonic imaging in the diagnosis and treatment of hepatic tumors Springer Tokyo

    Google Scholar 

  10. M Kitano M Kudo H Sakamoto N Fukuta R Nakaoka T Kawasaki (2004) ArticleTitleDynamic imaging of pancreatic disease by contrast-enhanced coded phase inversion harmonic ultrasonograpy Gut 53 854–9 Occurrence Handle10.1136/gut.2003.029934 Occurrence Handle1:STN:280:DC%2BD2c3jvFyjtQ%3D%3D Occurrence Handle15138213

    Article  CAS  PubMed  Google Scholar 

  11. MP Jensen P Karoly S Braver (1986) ArticleTitleThe measurement of clinical pain intensity: a comparison of six methods Pain 27 117–26 Occurrence Handle10.1016/0304-3959(86)90228-9 Occurrence Handle1:STN:280:BiiD28njvFM%3D Occurrence Handle3785962

    Article  CAS  PubMed  Google Scholar 

  12. V Heinemann MM Schermuly P Stieber L Schulz D Jungst R Wilkowski (1999) ArticleTitleCA19-9 a predictor of response in pancreatic cancer treated with gemcitabine and cisplatin Anticancer Res 19 2433–5 Occurrence Handle1:CAS:528:DyaK1MXlvVCmsL8%3D Occurrence Handle10470171

    CAS  PubMed  Google Scholar 

  13. H Gogas FJ Lofts TR Evans S Daryanani JL Mansi (1998) ArticleTitleAre serial measurements of CA19-9 useful in predicting response to chemotherapy in patients with inoperable adenocarcinoma of the pancreas? Br J Cancer 77 325–8 Occurrence Handle1:STN:280:DyaK1c7itV2jsQ%3D%3D Occurrence Handle9461005

    CAS  PubMed  Google Scholar 

  14. AB Miller B Hoogstraten M Staguet A Winkler (1981) ArticleTitleReporting results of cancer treatment Cancer 47 207–14 Occurrence Handle1:STN:280:Bi6C3M7ns1E%3D Occurrence Handle7459811

    CAS  PubMed  Google Scholar 

  15. ML Rothenberg MJ Moore MC Cripps JS Andersen RK Portenoy HA Burris SuffixIII et al. (1996) ArticleTitleA phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer Ann Oncol 7 347–53 Occurrence Handle1:STN:280:BymA1MbktlY%3D Occurrence Handle8805925

    CAS  PubMed  Google Scholar 

  16. ES Casper MR Green DP Kelsen (1996) ArticleTitlePhase II trial of gemcitabine in patients with adenocarcinoma of the pancreas Invest New Drugs 12 29–34

    Google Scholar 

  17. G Daniel MD Haller (2003) ArticleTitleChemotherapy for advanced pancreatic cancer Int J Radiat Oncol Biol Phys 56 16–23

    Google Scholar 

  18. JD Berlin P Atalano JP Thomas JW Kugler DG Haller AB Benson SuffixIII (2002) ArticleTitlePhase III study of gemcitabine in combination with fluororacil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297 J Clin Oncol 20 3270–5 Occurrence Handle10.1200/JCO.2002.11.149 Occurrence Handle1:CAS:528:DC%2BD38XmsF2rs74%3D Occurrence Handle12149301

    Article  CAS  PubMed  Google Scholar 

  19. AM Storniolo NH Enas CA Brown M Voi ML Rothenberg R Schilsky (1999) ArticleTitleAn investigational new drug treatment program for patients with gemcitabine: results for over 3000 patients with pancreatic carcinoma Cancer 85 1261–8 Occurrence Handle10.1002/(SICI)1097-0142(19990315)85:6<1261::AID-CNCR7>3.0.CO;2-T Occurrence Handle1:CAS:528:DyaK1MXitVequ70%3D Occurrence Handle10189130

    Article  CAS  PubMed  Google Scholar 

  20. InstitutionalAuthorNameRocha Lima CMS (2003) ArticleTitleA randomized phase 3 study comparing efficacy and safety of gemcitabine (GEM) and irinotecan (I), to GEM alone in patients with locally advanced or metastatic pancreatic cancer who have not received prior systemic therapy Proc Am Soc Clin Oncol 22 251

    Google Scholar 

  21. PA Philip MM Zalupski VK Vaitkevicius P Arlauskas R Chaplen LK Heilbrun et al. (2001) ArticleTitlePhase II study of gemcitabine and cisplatin in the treatment of patients with advanced pancreatic carcinoma Cancer 91 569–77

    Google Scholar 

  22. H Ulrich GV Kornek ML Raderer (2000) ArticleTitleA phase III trial of biweekly high dose gemcitabine for patients with metastatic pancreatic adenocarcinoma Cancer 88 2505–11

    Google Scholar 

  23. N Takeuchi S Maejima O Hasebe Y Mastuda K Hanazaki S Kaijima et al. (2004) ArticleTitleClinical problem in gemcitabine treatment for unresectable pancreatic cancer in the elderly: a multicentric retrospective study of 53 cases Jpn J Cancer Chemother 31 1987–91

    Google Scholar 

  24. K Hanada F Hino H Amano H Ooe Y Hirota S Sasao et al. (2002) ArticleTitleGemcitabine in elderly patients with unresectable pancreas cancer Jpn J Cancer Chemother 29 2521–5

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Gastroenterology and Hepatology, Kinki University School of Medicine, 377-2 Ohno-Higashi, Osaka-Sayama, 589-8511, Japan

    Hiroki Sakamoto, Masayuki Kitano, Yoichirou Suetomi & Masatoshi Kudo

  2. Department of Surgery, Kinki University School of Medicine, Osaka, Japan

    Yoshifumi Takeyama, Harumasa Ohyanagi, Takuya Nakai & Chikao Yasuda

Authors
  1. Hiroki Sakamoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Masayuki Kitano
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yoichirou Suetomi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Yoshifumi Takeyama
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Harumasa Ohyanagi
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Takuya Nakai
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Chikao Yasuda
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Masatoshi Kudo
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Sakamoto, H., Kitano, M., Suetomi, Y. et al. Comparison of standard-dose and low-dose gemcitabine regimens in pancreatic adenocarcinoma patients: a prospective randomized trial. J Gastroenterol 41, 70–76 (2006). https://doi.org/10.1007/s00535-005-1724-7

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00535-005-1724-7

Key words

Search

Navigation